Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Inhibitor TherapeuticsINTI EV-to-FCF is -4.15 as of Aug. 01, 2026. The stock has 1 warning sign investors should review. Among 345 Biotechnology companies, Inhibitor Therapeutics ranks worse than 289854.78% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Inhibitor Therapeutics's Enterprise Value is $12.57 Mil.
Inhibitor Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-3.03 Mil. Therefore, Inhibitor Therapeutics's EV-to-FCF for today is -4.15.
The historical rank and industry rank for Inhibitor Therapeutics's EV-to-FCF or its related term are showing as below:
INTI'
s EV-to-FCF Range Over the Past 10 Years
Min: -4.53 Med: 0 Max: 0
Current: -4.15
INTI's EV-to-FCF is ranked worse than 100% of 345
companies
in the Biotechnology industry
Industry Median: 14.39
vs INTI: -4.15
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Inhibitor Therapeutics's PE Ratio (TTM) for today is calculated as:
Inhibitor Therapeutics's share price for today is $0.08.
Inhibitor Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.010.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Inhibitor Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inhibitor Therapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Inhibitor Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Inhibitor Therapeutics's EV-to-FCF falls into.
Inhibitor Therapeutics's current Enterprise Value is $12.57 Mil.
Inhibitor Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inhibitor Therapeutics (INTI) has a EV-to-FCF of -4.15 as of Aug. 01, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Inhibitor Therapeutics and its competitors. According to the industry distribution chart, Inhibitor Therapeutics ranks #999999 out of 345 companies in the Biotechnology industry.
Is Inhibitor Therapeutics' EV-to-FCF too high?
Inhibitor Therapeutics' current EV-to-FCF is -4.15. Based on the distribution chart, Inhibitor Therapeutics ranks #999999 out of 345 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Inhibitor Therapeutics' EV-to-FCF compare to TPST and AKTX?
According to the Biotechnology industry distribution chart, Inhibitor Therapeutics ranks #999999 out of 345 companies for EV-to-FCF. This places Inhibitor Therapeutics in the lower half of its industry. The industry median EV-to-FCF is 14.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.39, based on 345 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Inhibitor Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inhibitor Therapeutics's current EV-to-FCF is -4.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inhibitor Therapeutics stock overvalued right now?
Inhibitor Therapeutics (INTI) has a current EV-to-FCF of -4.15. The current EV-to-FCF is -4.15. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Inhibitor Therapeutics (INTI), the current EV-to-FCF is -4.15 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Inhibitor Therapeutics Inc is a pharmaceutical development company focused on developing and potentially commercializing therapeutics based on already approved active pharmaceutical ingredients, with a primary focus on basal cell carcinoma nevus syndrome (BCCNS), also known as Gorlin Syndrome. The Company develops therapeutics with patent-protected methods of use or delivery for certain cancers and non-cancerous proliferation disorders, and focuses on therapies for basal cell carcinoma (BCC) in the United States, utilizing itraconazole, an FDA-approved drug for fungal infections, with developed intellectual property and know-how related to the treatment of cancer patients using itraconazole.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INTI has been successfully added to your 
